Navigation Links
Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
Date:5/17/2009

consistent with previous studies, the most frequently reported side effects were gastrointestinal symptoms and rash.

An exploratory analysis of pooled data from both trials revealed that treatment with pirfenidone resulted in a 30% relative reduction in the percentage of patients who experienced an absolute decline in percent predicted FVC of at least 10%. This magnitude of decline is considered clinically meaningful as a decline in percent predicted FVC as small as 5% over a six-month period has been shown to be an independent predictor of mortality in patients with IPF, as reported in the du Bois presentation at ATS.

InterMune expects to submit a new drug application (NDA) to the FDA in the summer of 2009 and a marketing authorization application (MAA) to the European authorities around the end of 2009.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects a total of approximately 200,000 people in the United States and Europe, with approximately 30,000 new cases developing in the United States alone, each year. There are no medicines approved by the U.S. Food and Drug Administration (FDA) or European Medicines Evaluation Agency (EMEA) for the treatment of IPF. On October 16, 2008, pirfenidone was approved for marketing in Japan as Pirespa(R), the first regulatory approval of any treatment for IPF in any major market in the world. IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough. IPF is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years.

About Pirfenidone

Prior in-vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreas
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. CMSA Delivers Important Message to Congress: Case Management Services Improve Patient Care and Should Be Key Strategy in Health Care Reform Initiatives
2. What Motivates Physicians to Succeed? Money Isn't Most Important
3. Major statin study reveals several important findings for reducing prostate cancer and disease
4. Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards
5. New Research Shows Tree Nuts May Play an Important Role in the Health of People With Diabetes
6. UT Southwestern researchers reveal how the brain processes important information
7. Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi
8. AUDIO from Medialink and Mens Health Network: Important Decision Regarding Prostate Cancer
9. Penn researchers identify new protein important in breast cancer genes role in DNA repair
10. Important new model shows how proteins find the right DNA sequences
11. Why Blood and Bone Marrow Donors Are So Important: Extreme Makeover: Home Edition Profiles Blood Drive Honoree Lizzie Bell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... http://www.marijuanastock.net , recently launched a “Video” section ... different cannabis companies in the marijuana industry made ... section, a website visitor is given access to ... relevant to marijuana-related businesses and the issues they ...
(Date:9/17/2014)... 17, 2014 NetDimensions (AIM: NETD; OTCQX: ... management systems, announces the opening of the 2014 Next ... , "We are very excited to meet up in ... interest in Next Steps from our clients and partners, ... really is. We look forward to some very engaging ...
(Date:9/17/2014)... 2014 Tina Griffin, a Senior Sales Associate ... chemotherapy but not her fight against cancer. Though weakened by ... Suncoast “Race for the Cure” on Saturday, Oct. 11, in ... Race for the Cure because I wanted to make an ... As part of her efforts, she is asking those who ...
(Date:9/17/2014)... Angeldress.co.uk is a popular online supplier; ... for worldwide clients. According to Leo, the company’s marketing ... first flagship retail store. Moreover, it is a market ... unveiled its new range of amazing wedding dresses and ... products are offered at greatly discounted prices, from 20% ...
(Date:9/17/2014)... September 17, 2014 In a new ... Dr. William Groff, an expert on the condition known as ... Pearly penile papules , or PPP, is a condition that ... other men may be affected as well. The condition is ... , “While PPP is not a sexually transmitted disease ...
Breaking Medicine News(10 mins):Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3
... low for people who suffer from traumatic brain injury ... function. TBI can impair a patient,s mental abilities, impact ... And long-term medical treatment carries a high economic cost. ... Air Force, Prof. Chaim Pick of Tel Aviv University,s ...
... , This release is available in German ... Foundation) is to establish 20 Collaborative Research Centres (CRCs) by ... Committee at its spring session in Bonn. The new CRCs ... percent programme allowance for indirect project costs) for the initial ...
... not won in a single battle: Long after a cancer has ... is under debate, and much is unclear. New research led by ... blood cancer, the source of cancer recurrence is in a set ... cells, and thus able to survive chemotherapy. The findings, which appeared ...
... TUESDAY, May 29 (HealthDay News) -- People with less than ... problems with their thinking skills later in life, according to ... researchers from Harvard University noted that people with more education ... thinking, or so-called "cognitive," skills, even if they had the ...
... Dotinga HealthDay Reporter , MONDAY, May 28 (HealthDay ... pounds because her friends sit around? A small study ... after-school programs if they hung out with active kids, and ... that friends directly affect how active kids are, and it,s ...
... treatment for suspected HIV is critical, pre-exposure preventive treatment ... people in high-risk groups, states a review of evidence ... "Although postexposure prophylaxis has a long history of ... treatment in the course of infection ("treatment as prevention") ...
Cached Medicine News:Health News:Diabetes drug could be a promising therapy for traumatic brain injury 2Health News:Diabetes drug could be a promising therapy for traumatic brain injury 3Health News:DFG establishes 20 new Collaborative Research Centres 2Health News:DFG establishes 20 new Collaborative Research Centres 3Health News:DFG establishes 20 new Collaborative Research Centres 4Health News:DFG establishes 20 new Collaborative Research Centres 5Health News:DFG establishes 20 new Collaborative Research Centres 6Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Education May Protect Brain From Exposure to Solvents 2Health News:Key to More Active, Slimmer Kids: Friends 2Health News:Antiretroviral treatment for preventing HIV infection: an evidence review for physicians 2
(Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
(Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Medicine Products: